Your browser doesn't support javascript.
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters.
Halfmann, Peter J; Iida, Shun; Iwatsuki-Horimoto, Kiyoko; Maemura, Tadashi; Kiso, Maki; Scheaffer, Suzanne M; Darling, Tamarand L; Joshi, Astha; Loeber, Samantha; Singh, Gagandeep; Foster, Stephanie L; Ying, Baoling; Case, James Brett; Chong, Zhenlu; Whitener, Bradley; Moliva, Juan; Floyd, Katharine; Ujie, Michiko; Nakajima, Noriko; Ito, Mutsumi; Wright, Ryan; Uraki, Ryuta; Warang, Prajakta; Gagne, Matthew; Li, Rong; Sakai-Tagawa, Yuko; Liu, Yanan; Larson, Deanna; Osorio, Jorge E; Hernandez-Ortiz, Juan P; Henry, Amy R; Ciuoderis, Karl; Florek, Kelsey R; Patel, Mit; Odle, Abby; Wong, Lok-Yin Roy; Bateman, Allen C; Wang, Zhongde; Edara, Venkata-Viswanadh; Chong, Zhenlu; Franks, John; Jeevan, Trushar; Fabrizio, Thomas; DeBeauchamp, Jennifer; Kercher, Lisa; Seiler, Patrick; Gonzalez-Reiche, Ana Silvia; Sordillo, Emilia Mia; Chang, Lauren A; van Bakel, Harm.
  • Halfmann PJ; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Iida S; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Iwatsuki-Horimoto K; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Maemura T; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Kiso M; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Scheaffer SM; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Darling TL; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Joshi A; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Loeber S; Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Singh G; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Foster SL; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ying B; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Case JB; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Chong Z; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Whitener B; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Moliva J; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Floyd K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Ujie M; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Nakajima N; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Ito M; Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.
  • Wright R; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Uraki R; Influenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA.
  • Warang P; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Gagne M; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
  • Li R; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Sakai-Tagawa Y; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Liu Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Larson D; Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
  • Osorio JE; Division of Virology, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
  • Hernandez-Ortiz JP; Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
  • Henry AR; Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
  • Ciuoderis K; Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA.
  • Florek KR; Colombia/Wisconsin One-Health Consortium and One-Health Genomic Laboratory, Universidad Nacional de Colombia, Medellín, Colombia.
  • Patel M; Colombia/Wisconsin One-Health Consortium and One-Health Genomic Laboratory, Universidad Nacional de Colombia, Medellín, Colombia.
  • Odle A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
  • Wong LR; Colombia/Wisconsin One-Health Consortium and One-Health Genomic Laboratory, Universidad Nacional de Colombia, Medellín, Colombia.
  • Bateman AC; Wisconsin State Laboratory of Hygiene, Madison, WI, USA.
  • Wang Z; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • Edara VV; Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
  • Chong Z; Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.
  • Franks J; Wisconsin State Laboratory of Hygiene, Madison, WI, USA.
  • Jeevan T; Department of Animal Dairy, and Veterinary Sciences, College of Agriculture and Applied Sciences, Utah State University, Logan, UT, USA.
  • Fabrizio T; Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta, Department of Pediatrics, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA.
  • DeBeauchamp J; Department of Medicine, Washington University School of Medicine, St Louis, MO, USA.
  • Kercher L; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Seiler P; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Gonzalez-Reiche AS; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Sordillo EM; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Chang LA; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • van Bakel H; Department of Infectious Diseases, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Nature ; 603(7902): 687-692, 2022 03.
Article in English | MEDLINE | ID: covidwho-1641974
ABSTRACT
The recent emergence of B.1.1.529, the Omicron variant1,2, has raised concerns of escape from protection by vaccines and therapeutic antibodies. A key test for potential countermeasures against B.1.1.529 is their activity in preclinical rodent models of respiratory tract disease. Here, using the collaborative network of the SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme of the National Institute of Allergy and Infectious Diseases (NIAID), we evaluated the ability of several B.1.1.529 isolates to cause infection and disease in immunocompetent and human ACE2 (hACE2)-expressing mice and hamsters. Despite modelling data indicating that B.1.1.529 spike can bind more avidly to mouse ACE2 (refs. 3,4), we observed less infection by B.1.1.529 in 129, C57BL/6, BALB/c and K18-hACE2 transgenic mice than by previous SARS-CoV-2 variants, with limited weight loss and lower viral burden in the upper and lower respiratory tracts. In wild-type and hACE2 transgenic hamsters, lung infection, clinical disease and pathology with B.1.1.529 were also milder than with historical isolates or other SARS-CoV-2 variants of concern. Overall, experiments from the SAVE/NIAID network with several B.1.1.529 isolates demonstrate attenuated lung disease in rodents, which parallels preliminary human clinical data.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Disease Models, Animal / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04441-6

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Disease Models, Animal / SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Prognostic study Topics: Vaccines / Variants Limits: Animals / Female / Humans / Male Language: English Journal: Nature Year: 2022 Document Type: Article Affiliation country: S41586-022-04441-6